Your session is about to expire
← Back to Search
HyperSight Imaging arm for Head and Neck Cancers
N/A
Waitlist Available
Research Sponsored by Varian, a Siemens Healthineers Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patient has biopsy confirmed malignancy and recommendation for definitive or palliative radiation to the head and neck, breast, lungs, upper GI structures, or pelvis.
Patient has ECOG performance status 0-2.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
Study Summary
This trial aims to test a new imaging technology called "HyperSight" that may improve the accuracy and quality of radiation therapy. Currently, there are limitations with the current imaging technology, including long acquisition
Who is the study for?
This trial is for individuals with various cancers (pelvic, head and neck, breast, lung, gastric, gastrointestinal tumors) who require precise radiation therapy. Participants should need image-guided radiation treatment but are not specified by other inclusion or exclusion criteria in the provided information.Check my eligibility
What is being tested?
The study is testing 'HyperSight Imaging,' a new type of imaging technology designed to improve the accuracy of radiation therapy. It aims to overcome limitations like long scan times and poor image quality seen with conventional cone beam computed tomography (CBCT).See study design
What are the potential side effects?
Since this trial focuses on an imaging technique rather than a drug or biological therapy, traditional side effects are not applicable. However, there may be risks associated with exposure to additional radiation from improved imaging if used frequently.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have a confirmed cancer diagnosis and need radiation therapy in specific areas.
Select...
I am able to get out of my bed or chair and move around.
Select...
I am 18 years old or older.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Fraction of patients whose HyperSight CBCT images meet the criteria for CBCT-based treatment planning.
Secondary outcome measures
Breath hold tolerance
Comparison of anatomical structure contours defined on HyperSight and conventional imaging.
Fraction of patients whose HyperSight CBCT images meet the criteria for CBCT-based treatment planning by anatomical site
+6 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: HyperSight Imaging armExperimental Treatment1 Intervention
Subjects are imaged with the new HyperSight CBCT imaging system.
Find a Location
Who is running the clinical trial?
Varian, a Siemens Healthineers CompanyLead Sponsor
30 Previous Clinical Trials
7,213 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger